Medicilon has 50⁺Payloads，200⁺Linkers，30⁺Payloads+Linkers. Up until the end of 2022, Medicilon undertook more than 100 major IND application biopharmaceutical projects, including monoclonal antibodies, bispecific antibodies, polyclonal antibodies, ADCs, viral vaccines and fusion proteins. As of May 8, 2023, Medicilon has successfully assisted 17 ADC drugs to obtain clinical approval, and more than 10 ADC projects are in development.

Medicilon has access to many of the popular POI ligands and multiple tissue types of E3 ligase ligands, in addition to having established a linker library containing hundreds of diverse molecules.As of the end of June 2023, Medicilon has successfully assisted 5 PROTAC drugs to abtain clinical approval, and more than 20 PROTAC projects are under development.

The Medicilon nucleotide drug R&D platform can provide a one-stop option for monomer synthesis and modification; oligonucleotide synthesis; delivery system synthesis and oligonucleotide conjugate synthesis. The siRNA library that has been built has a rich monomer inventory anda large monomer synthesis building block library, to support the synthesis of various modified monomers.